➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
AstraZeneca
McKinsey
Harvard Business School
McKesson

Last Updated: September 18, 2021

DrugPatentWatch Database Preview

Claims for Patent: 5,747,340

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 5,747,340
Title: Targeted gene expression using preproendothelin-1 promoters
Abstract:This invention provides a vector for expression of a nucleic acid cassette in bronchial epithelial and vascular endothelial cells comprising a segment of the 5\'-flanking region of the preproendothelin-1 gene, upstream from the transcription start site, the first exon of the preproendothelin-1 gene, and a nucleic acid cassette, wherein the nucleic acid cassette is located within the first exon, in sequential and positional relationship for expression of the nucleic acid cassette.
Inventor(s): Harats; Dror (Ramat-Gan, IL), Kurihara; Hiroki (Toyko, JP), Belloni; Paula Nanette (Moss Beach, CA), Sigal; Charles Elliott (San Francisco, CA)
Assignee: Syntex (U.S.A.) Inc. (Palo Alto, CA)
Application Number:08/395,742
Patent Claims:1. A vector for expression of a nucleic acid casette comprising a murine preproendothelin-1 gene 5'-flanking segment, the first exon of the preproendothelin-1 gene, and a nucleic acid cassette, wherein the nucleic acid cassette is located within the first exon, in sequential and positional relationship for expression of the nucleic acid cassette.

2. A vector of claim 1 further comprising the first intron of the preproendothelin-1 gene, said intron located downstream from the first exon.

3. A vector of claim 2 comprising about 0.8 kb of the first intron.

4. A vector of claim 3 wherein the nucleic acid cassette is positioned between the noncoding and coding regions of said exon, in sequential and positional relationship for expression of the nucleic acid cassette.

5. A vector of claim 1 wherein the segment of the 5'-flanking region comprises about the first 0.45 kb upstream from the transcription start site.

6. A vector of claim 1 wherein the segment of the 5'-flanking region comprises about the first 1.4 kb upstream from the transcription start site.

7. A vector of claim 1 wherein the segment of the 5'-flanking region comprises about the first 5.9 kb upstream from the transcription start site.

8. A vector of claim 1 wherein the segment of the 5'-flanking region comprises about the first 9.1 kb upstream from the transcription start site.

9. A vector of claim 3 comprising 0.45 kb of the 5'-flanking region, the first exon, and about 0.8 kb of the first intron of the preproendothelin-1 gene.

10. A vector of claim 3 comprising 1.4 kb of the 5'-flanking region, the first exon, and about 0.8 kb of the first intron of the preproendothelin-1 gene.

11. A vector of claim 3 comprising 5.9 kb of the 5'-flanking region, the first exon, and about 0.8 kb of the first intron of the preproendothelin-1 gene.

12. A vector of claim 1 wherein the cassette comprises a nucleic acid sequence encoding a protein, a polypeptide, a ribozyme, or an antisense RNA.

13. The isolated genomic murine preproendothelin-1 5'-flanking region.

14. A plasmid comprising the 5'-flanking region of claim 13.

15. A method for expressing a gene of interest in vascular endothelial or bronchial epithelial cells which method comprises transfecting the cells with a vector of claim 1.

Details for Patent 5,747,340

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ⤷  Free Forever Trial Syntex (U.S.A.) Inc. (Palo Alto, CA) 2015-05-05 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ⤷  Free Forever Trial Syntex (U.S.A.) Inc. (Palo Alto, CA) 2015-05-05 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ⤷  Free Forever Trial Syntex (U.S.A.) Inc. (Palo Alto, CA) 2015-05-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Harvard Business School
McKinsey
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.